Search
Biotech CEO Sisterhood: Named CEO of Acadia Pharmaceuticals in September, Catherine Owen Adams describes taking the leap from a career in 'pharma' to running an independent, commercial stage biotech
Interviewed by Sisterhood editorial board member Julia Owens, Catherine Owen Adams shares her career journey, and discusses the perceived...
Apr 22, 2025
BioVenture VoiCes Episode 17: Norwest Venture Partners' Tiba Aynechi
Tiba Aynechi describes her career path, which has been spent entirely in the Bay Area since she earned her PhD from UCSF in the early...
Apr 21, 2025
On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73
He describes the market potential of the company's HIF-2⍺, a target that has already been de-risked by a large pharma, why he believes...
Apr 17, 2025
As federal funding for cancer research has been jeopardized at NIH and academia, Parker Institute for Cancer Immunotherapy is one private institution ready to step up and broaden its impact
CSO John Connolly describes how recent new hires and a willingness to lead will expand PICI's already broad reach in cancer research...
Apr 16, 2025
Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies
Founder and CEO Nicole Paulk describes the process, which allows the public to invest as little as $100, and why she views the investors...
Apr 16, 2025
Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)
CEO Rick Winningham describes the science behind ampreloxetine, and the rationale for developing it for patients with multiple system...
Apr 15, 2025
Marea Therapeutics today announced acceptance of a late-breaker at #EASCongress2025 for its ANGPTL4 inhibitor - believed to be the first ever clinical data presented for this lipid lowering target
CEO Josh Lehrer and CSO Ethan Weiss describe the biology of the target and highlight the topline data, which was first announced at...
Apr 15, 2025
After switching to a new GalNAc-LNP delivery vehicle a year ago, Verve Therapeutics today announced the initial safety and efficacy data from its VERVE-102 PCSK9 base editor
Co-Founder & CEO Sek Kathiresan walks us through the data, which so far has showed a clean safety profile and an impressive ability to...
Apr 14, 2025
Mount Sinai has embraced AI as a drug discovery tool by launching this month its new AI Small Molecule Drug Discovery Center - Professor Avner Schlessinger tells us why
Dr. Schlessinger describes how the new center is meant to speed up drug discovery work and enable Mount Sinai researchers to develop...
Apr 10, 2025
Off-Target Effects Episode 2: Matt speaks with Avoro Capital's Behzad Aghazadeh about the hot button issues that have been striking the biotech sector
One of the largest and most successful biotech investors, Dr. Aghazadeh is asked about key current events like turnover at FDA, tariffs,...
Apr 10, 2025
Jones Healthcare & Technology Innovation Conference: Jones Research analysts Soumit Roy and Justin Walsh share their take on biotech and comment on companies they cover
They discusses takeaways from the conference, and comment on Beam, Korro, Wave, Intellia, Prime, Janux, Alto Nuero, Rapport, and YmAbs....
Apr 9, 2025
Jones Healthcare & Technology Innovation Conference: Pharvaris is developing oral bradykinin B2 receptor inhibitors for HEA - with a first pivotal scheduled to read in less than a year
CFO David Nassif describes the unmet need that still exists today in HAE, and updates us on programs in both the acute and prophylactic...
Apr 9, 2025
Jones Healthcare & Technology Innovation Conference: Biotech veteran David Hung on his company Nuvation Bio, which has an FDA decision for its ROS1 scheduled for June
He describes where this fits into the ROS1 space, and the data that has been derived for the filing. Plus, mIDH1, drug-drug-conjugates,...
Apr 9, 2025
Jones Healthcare & Technology Innovation Conference: Wave CEO Paul Bolno discusses recent DMD data and regulatory feedback, and shares updates on alpha-1 antitrypsin, obesity, and Huntington's
He describes the 48 week data for the exon 53 DMD program, and discusses the company's plan to seek accelerated approval. Plus, guidance...
Apr 9, 2025
Jones Healthcare & Technology Innovation Conference: The CIO of XOMA Royalty describes the inner workings of the royalty business, and also how to help with biotech's negative enterprise problem
Brad Sitko describes how XOMA is able to do smaller deals than other larger investors in this space, and he gives examples of investments...
Apr 9, 2025
Jones Healthcare & Technology Innovation Conference: Trevi Therapeutics CEO Jennifer Good describes recent positive data in refractory chronic cough and previews upcoming IPF data
She describes how the mechanism of Haduvio differs from other programs in chronic cough, and covers the recent phase 2a RIVER data....
Apr 9, 2025
Jones Healthcare & Technology Innovation Conference: Jones Research analysts Catherine Novack and Debanjana Chatterjee share their take on biotech and comment on companies they cover
They discusses the macro and regulatory factors that have affected the sector so strongly, and comment on Wave, Korro, ProQr, Capricor,...
Apr 9, 2025
Biotech CEO Sisterhood: X4 Pharmaceuticals' CEO Paula Ragan on her career and running a commercial stage company in the rare disease space
Interviewed by Sisterhood editorial board member Erika Smith, Paula Ragan shares her career path and things she has learned along the...
Apr 8, 2025
Checking in on the progress of Trinity by Breakthrough in Oxford, UK
After its recent topping off ceremony, BiotechTV's Amy Brown checked in on the construction progress of Trinity by Breakthrough...
Apr 8, 2025
Elias Zerhouni and Andy Plump discuss the future of multispecific biologics
Interviewed by Andy Plump, President of R&D at Takeda, Dr. Zerhouni discusses the rationale for multispecifics and the science behind...
Apr 7, 2025
.png){kind=logo}
